- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02881138
A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors
July 28, 2020 updated by: RemeGen Co., Ltd.
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive
Study Overview
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed informed consent form;
- Aged 18-65 years;
- ECOG physical condition is 0 or 1;
- Life expectancy greater than 12 weeks;
- Diagnosed with histologically or cytologically-confirmed, standard treatment is ineffective (disease progresses after treatment) or HER2-positive, locally advanced or metastatic malignant solid tumor patients who cannot tolerate standard therapy, cannot receive or do not have standard therapy;
- Human epidermal growth factor receptor 2 (HER2)-positive as measured either by immunohistochemistry (IHC 2+ and by fluorescence in situ hybridization (FISH) or by immunohistochemistry (3+);
- Patients with measurable and appreciable tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1);
Adequate organ function as defined by the following criteria:
- absolute neutrophil count(ANC) >= 1.5 x 10(9)/L;
- platelets>=100*10(9)/L;
- Total serum bilirubin <=1.5*ULN;
- serum aspartate transaminase (AST) and serum alanine transaminase (ALT) <=2.5*upper limit of normal (ULN), or AST and ALT<=5*ULN with hepatic metastasis;
- Serum creatinine clearance rate >=45ml/min;
- international normalized ratio (INR) and activated partial thromboplastin time (APTT) must be less than or equal to 1.5 times the upper limit of the normal range (ULN);
- Women of child-bearing potential and men must agree to use adequate contraception (e.g. condoms, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete sexual abstinence, or sterilized partner) prior to study entry and during the period of therapy and for 30 days after the last dose of study drug;
- Left ventricular ejection fraction (LVEF) >= 50%.
Exclusion Criteria:
- Current pregnancy or lactation;
- Received anti-tumor treatment 4 weeks before study administration, including chemotherapy, radiotherapy, hormone therapy, biological therapy or immunotherapy, except the following: Gonadotropin-releasing hormone (GnRH) antagonistic therapy for prostate cancer and Hormone replacement therapy;
- Major surgery within 4 weeks of first dose of study drug and not fully recovered;
- Receiving palliative radiation therapy for bone metastases if administered <= 2 weeks prior to first study treatment;
- Toxicity of previous anti-tumor treatment has not recovered to CTCAE [version 4.0] 0-1 (with exception of alopecia);
- Participated in other clinical drug studies within 4 weeks;
- Hypersensitivity or delayed allergic reaction to certain components of RC48-ADC or similar drugs;
- According to the judgment of the investigator, a clinically significant active infection;
- A history of immunodeficiency, including a positive HIV test, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;
- Uncontrollable systemic diseases including diabetes, hypertension, lung Fibrosis, acute lung disease, interstitial lung disease, etc.;
- Congestive heart failure with grade 2 or higher (including grade 2) by the New York Institute of Cardiology (NYHA) of the United States in the history of diseases such as acute myocardial infarction, unstable angina, stroke, or transient ischemic attack within 6 months before enrollment;
- Insufficient adherence to participate in this clinical study;
- Treated with Herceptin (Trastuzumab) within 60 days before the trial;
- Have received systemic steroid therapy for a long time ( short-term users who discontinue medication> 2 weeks can be selected);
- Uncontrolled primary or metastatic tumor of brain;
- Peripheral neuropathy with grade>= 2;
- People with a history of mental illness that is difficult to control.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RC48-ADC
Participants will be allocated to one of the following dose groups: 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC48-ADC followed by 28 days of dose limited toxicity (DLT) observation period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
maximal tolerance dose (MTD) of RC48-ADC
Time Frame: DLT will be evaluated on 28 days of observation period
|
Maximum-tolerated dose (MTD) was defined as the highest dose level at which no more than one of six patients experienced DLT during the DLT assessment window.
|
DLT will be evaluated on 28 days of observation period
|
AEs
Time Frame: Estimated 2 years
|
The drug safety was assessed by investigator(s) according to NCI-CTCAE v4.0
|
Estimated 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: Estimated 2 years
|
Maximum Observed Plasma Concentration
|
Estimated 2 years
|
AUC
Time Frame: Estimated 2 years
|
Area Under Curve
|
Estimated 2 years
|
Tmax
Time Frame: Estimated 2 years
|
Time for Cmax
|
Estimated 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2016
Primary Completion (Actual)
April 30, 2020
Study Completion (Actual)
July 15, 2020
Study Registration Dates
First Submitted
August 20, 2016
First Submitted That Met QC Criteria
August 25, 2016
First Posted (Estimate)
August 26, 2016
Study Record Updates
Last Update Posted (Actual)
July 30, 2020
Last Update Submitted That Met QC Criteria
July 28, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C001 CANCER
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
NeuPharma, Inc.RecruitingLocally Advanced Solid Tumors | Metastatic Solid TumorsUnited States
Clinical Trials on RC48-ADC
-
Cancer Institute and Hospital, Chinese Academy...RecruitingMetastatic Breast CancerChina
-
RemeGen Co., Ltd.Completed
-
Tianjin Medical University Cancer Institute and...Chongqing University Cancer Hospital; Xiangya Hospital of Central South University and other collaboratorsNot yet recruitingNeoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
-
RemeGen Co., Ltd.RecruitingMuscle Invasive Bladder CarcinomaChina
-
Chinese PLA General HospitalRecruitingAdvanced Gastroesophageal AdenocarcinomaChina
-
Peking Union Medical College HospitalRecruitingSalivary Gland TumorsChina
-
RemeGen Co., Ltd.Completed
-
RemeGen Co., Ltd.Not yet recruitingNon-small Cell Lung CancerChina